Skip to main content
PMC home page
Springer logoLink to Springer
. 2021 Nov 9;36(3):561–567. doi: 10.1007/s10557-021-07291-y

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus

Bertram Pitt 1, Gabriel Steg 2, Lawrence A Leiter 3, Deepak L Bhatt 4,✉
PMCID: PMC9090862  PMID: 34750713

Abstract

Purpose

In patients with type 2 diabetes mellitus (T2DM), both sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide receptor agonists (GLP-1 RAs) have demonstrated significant improvements in cardiovascular and kidney outcomes independent of their glycemic benefits. This paper will briefly compare the effect of SGLT2is and GLP-1 RAs to that of the SGLT1/2 inhibitor sotagliflozin on the incidence of myocardial infarction (MI) and stroke in patients with T2DM and further postulate mechanisms to account for these findings.

Methods and Results

Thus far, the results from SCORED and SOLOIST (trials studying the SGLT1/2 inhibitor sotagliflozin) suggest that an increase in SGLT1 inhibition when added to SGLT2 inhibition may contribute to reductions in MI and stroke in patients with T2DM. This benefit is beyond what SGLT2is alone can accomplish and at least similar to GLP-1 RAs but with the added benefit of a reduction in hospitalizations and urgent visits for HF. Larger and longer studies are required to confirm the effectiveness of SGLT1/SGLT2 inhibition in reducing MI and stroke in patients with T2DM and elucidate the mechanisms associated with this finding.

Conclusions

The role of SGLT1/2 inhibition as an addition to GLP-1 RAs in patients with and without T2DM at increased risk for MI and stroke requires further study. Regardless, the finding that a relative increase in SGLT1/2 inhibition reduces the risk of MI and stroke as well as hospitalizations and urgent visits for heart failure could improve quality of life and reduce the healthcare burden associated with T2DM.

Keywords: Type 2 diabetes, Cardiovascular risk, Quality of life, Sodium-glucose cotransporter 1/2 inhibitors

In patients with type 2 diabetes mellitus, both sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide receptor agonists (GLP-1 RAs) have been shown to significantly improve cardiovascular and kidney outcomes independent of their effect on glycemia. Current guidelines, as well as a recent meta-analysis of SGLT2is and GLP-1 RAs, reflect the efficacy of these drug classes [1–4]. Although they significantly improve cardiovascular and kidney outcomes in patients with type 2 diabetes, their utility in preventing myocardial infarction (MI) and stroke is relatively modest and inconsistent, especially with SGLT2is.

The recent findings from the SCORED (10,584 patients with type 2 diabetes and CKD randomized to sotagliflozin or placebo) and SOLOIST (1222 patients with type 2 diabetes admitted with worsening heart failure randomized to sotagliflozin or placebo) trials suggest that like SGLT2is, SGLT1/2 s reduce the composite of deaths from cardiovascular causes, hospitalization for heart failure, and urgent visits for heart failure but may provide greater reduction in MI and stroke [5, 6]. Although there is no direct comparison of the SGLT1/2i sotagliflozin to the SGLT2is, a meta-analysis of SGLT2is has failed to show a reduction of stroke and only a modest reduction in the incidence of MI [3]. Therefore, the combination of SGLT1/SGLT2 inhibition may benefit patients with type 2 diabetes beyond what current therapeutic options can offer. Previously, we illustrated the benefit of a relative increase in SGLT1/SGLT2 inhibition with regard to reduction in stroke and MI [7]. This paper will briefly compare the effect of SGLT2is and GLP-1 RAs to that of the SGLT1/2 inhibitor sotagliflozin on the incidence of MI and stroke in patients with type 2 diabetes and further postulate mechanisms associated with SGLT1 inhibition that could account for these findings.

In general, SGLT2is reduce cardiovascular mortality, kidney outcomes, and heart failure hospitalizations (HHF). In contrast, GLP-1 RAs primarily reduce atherosclerotic events. A recent meta-analysis of 6 trials with unique individual data from 46,969 patients with type 2 diabetes found that SGLT2is significantly reduced the risk of major cardiovascular events (HR 0.90; 95% CI 0.85–0.95), HHF/cardiovascular mortality (HR 0.78; 95% CI 0.73–0.84), and kidney outcomes (HR 0.62; 95% CI 0.56–0.70) [3]. The presence or absence of atherosclerotic cardiovascular disease did not significantly modify the benefit for these adverse cardio-renal events. Overall, there was a modest reduction in MI (HR 0.91; 95% CI 0.84–0.99). In those with baseline ASCVD, MI was similarly reduced (HR 0.90; 95% CI 0.82–0.99). Thus, SGLT2is are effective in reducing the incidence of MI but their effects are modest and likely related to a reduction in myocardial oxygen demands rather than an effect on thrombosis [8]. Surprisingly, there was no overall reduction in stroke (HR 0.96; 95% CI 0.87–1.07), even in those with baseline atherosclerotic cardiovascular disease (HR 0.99; 95% CI 0.87–1.11) [3] despite the reductions in inflammatory cytokines, oxidative stress, visceral obesity, and blood pressure that occur with these agents [9]. The reasons SGLT2is fail to reduce the occurrence of MI to a greater degree and overall stroke remain uncertain, especially in view of their reduction in blood pressure which on the basis of prior epidemiologic studies should have predicted a reduction in stroke [10]. However, their resultant increase in erythropoietin and as a consequence hematocrit and blood viscosity [11], which could in part be attributed to the effect of SGLT2i to increase sodium excretion and to decrease plasma volume, could predispose to a slight increase in thrombosis [12], thereby offsetting the reduction in stroke that would otherwise be expected from the blood pressure lowering.

A meta-analysis of GLP-1 RAs from trials comprising 56,004 patients found a significant reduction in 3-point MACE (cardiovascular mortality, nonfatal MI, and nonfatal stroke) (HR 0.88, 95% CI 0.79–0.98), cardiovascular mortality (HR 0.88, 95% CI 0.76–0.94), all-cause mortality (HR 0.89, 95% CI 0.81–0.97), fatal and nonfatal stroke (HR 0.84, 95% CI 0.76–0.94), and HHF (HR 0.92, 95% CI 0.86–0.97) as well as a trend towards reduction in nonfatal and fatal MI (HR 0.91, 95% CI 0.82–1.02) [4]. In a sensitivity analysis using a less conservative statistical approach, there was significant benefit on fatal and nonfatal MI (HR 0.91, 95% CI 0.83–1.00; p = 0.039). The meta-analysis also found no increase in the incidence of hypoglycemia, pancreatitis, and pancreatic cancer in patients taking a GLP-1 RA compared with those on placebo [4]. However, the various GLP-1 RAs differ in structure, duration of action, and effects. The greatest reduction in fatal and nonfatal MI was seen in the HARMONY trial of albiglutide (HR 0.75; 95% CI 0.61–0.90) [13], but there was no significant reduction in fatal stroke (HR 0.86; 95% CI 0.65–1.14). SUSTAIN-6 [14] with subcutaneous semaglutide saw the greatest numerical reduction in fatal and nonfatal stroke, but it was not statistically significant (HR 0.65; 95% CI 0.41–1.03) in this smaller phase 3 trial (N = 3297) nor was this observed with oral semaglutide in PIONEER-6 [15] (HR 0.76; 95% CI 0.37–1.56). Similarly, fatal and nonfatal MI were not reduced significantly in SUSTAIN-6 (HR 0.81; 95% CI 0.57–1.16) or PIONEER-6 (HR 1.04; 95% CI 0.66–1.64).

A recent observational study from SWEDEHEART of patients with DM surviving their first MI found that patients taking a GLP-1 RA (86.6% on liraglutide) compared with standard diabetes care had numerically lower rates of myocardial reinfarction (HR 0.71; 95% CI 0.49–1.04) and stroke (HR 0.42; 95% CI 0.18–1.02) [16]. Although the impact on reinfarction and stroke was similar to that of sotagliflozin in SCORED and SOLOIST [5, 6], patients in this observational study were early post MI and at a high risk of recurrent MI and stroke, and the effects did not reach statistical significance [16].

Thus, despite similarity to SCORED (sotagliflozin) in the magnitude of reduction in both fatal and nonfatal MI and stroke with semaglutide in SUSTAIN-6 [14] and GLP-1 RAs (mainly liraglutide) in the SWEDEHEART observational study [16], the results were not statistically significant. Until further comparative studies are available, it is, however, reasonable to assume that the magnitude of benefit for MI and stroke reduction is similar in patients receiving an SGLT1/2 inhibitor or a GLP-1 RA. Of note, the reduction in HHF with GLP-1 RAs [4], although significant, is less than with the SGLT2is [3] and the SGLT1/2i sotagliflozin [5, 6].

Combining both types of agents may yield additional benefits: in a recent observational propensity-matched study from 3 US claims databases of 12,854 patients with type 2 diabetes who added an SGLT2i or sulfonylurea to baseline GLP-1 RA treatment, adding an SGLT2i produced greater cardiovascular benefit (comprising MI, stroke, all-cause mortality, and HHF) [17]. The magnitude of cardiovascular risk reduction echoed the pivotal cardiovascular outcome trials studying SGLT2is versus placebo, in which the baseline use of GLP-1 RAs was minimal. While the proposed mechanisms associated with the reduction in cardiovascular events with SGLT2is and GLP-1 RAs are complementary, further prospective trials will be required to determine whether or not the addition of an SGLT2i to a GLP-1 RA is additive or synergistic.

Evidence supports significant reduction in cardiovascular and kidney outcomes with both SGLT2is and GLP-1 RAs as well as potential benefit from their combination. Although evidence from preclinical studies suggests that SGLT2is reduce infarct size [18], the reduction in incidence of nonfatal and fatal MI in patients with type 2 diabetes on this treatment is modest, approximately 11% [3]. Rather than a direct effect on platelet activation, thrombus formation, or atherosclerotic plaque stability, this benefit is postulated to result from a reduction in preload with a resultant reduction in myocardial wall tension, myocardial oxygen demands, and a consequential reduction in myocardial ischemia [8]. Overall, SGLT2is have not been found to reduce the incidence of nonfatal and fatal stroke [3]. In contrast, GLP-1 RAs demonstrably reduce the incidence of nonfatal and fatal stroke [4], an effect credited to a reduction in thrombosis and an increase in atherosclerotic plaque stability [19, 20].

Therefore, although these medications provide substantial cardiovascular benefits, their protective effect against MI and stroke is modest given the impact of type 2 diabetes as a risk factor for MI as well as ischemic and hemorrhagic stroke. Patients with type 2 diabetes have greater mortality and worse stroke outcomes compared with patients without type 2 diabetes. MI is the primary cause of death in patients with type 2 diabetes. There is a > 20% risk of developing a first MI within the 10 years of developing type 2 diabetes. In patients who experienced MI, the risk of a recurrent one is > 40% [21]. Thus, strategies to prevent stroke and MI in patients with type 2 diabetes are crucial as we face the projected increase in type 2 diabetes over the next decade. The increased risk of stroke associated with prediabetes brings further urgency to stroke prevention in patients at risk of or with type 2 diabetes [22].

With this in mind, we point to the relative increase in SGLT1 vs SGLT2 inhibition with sotagliflozin resulting in a greater reduction in MI and stroke in SCORED [5] compared with the results of the meta-analysis of SGLT2is which failed to show a reduction in stroke [3] and a similar reduction as the GLP-1 RAs [4] but with a greater reduction in HHF. In SCORED [5], sotagliflozin reduced total fatal and nonfatal MI by 32% (HR 0.68, 95% CI 0.52–0.89, p = 0.004), total fatal and nonfatal stroke by 34% (HR 0.66, 95% CI 0.48–0.91, p = 0.012), and HHF and urgent visits for HF by 33% (HR 0.67; 95% CI 0.55–0.82, p ≤ 0.001).

The mechanisms associated with the development of MI and stroke in patients with type 2 diabetes include insulin resistance, increased formation of advanced glycation end products (AGEs), activation of protein kinase C isoforms, over activity of the hexose amine pathway, vascular calcification, an increase in reactive oxygen species (ROS), decreased nitric oxide availability, endothelial dysfunction, inflammatory cytokine activation, increased vascular stiffness, platelet activation, an increased risk of thrombosis, and an increase in plasma and blood viscosity as well as autonomic dysfunction [23, 24]. Chronic kidney disease (CKD) has been recognized as an important risk factor for stroke. However, recent studies suggest that the relationship between CKD and stroke is confounded by its connection to longstanding hypertension [25].

The mechanisms accounting for the reduction in MI and stroke with sotagliflozin in the SCORED [5] and SOLOIST trials [6] remain undetermined. SGLT1 is expressed not only in the brush border of the small intestine and proximal renal tubule but also in salivary glands, liver, pancreatic alpha cells, lungs, heart, skeletal muscle, brain, cervix of the uterus, stomach, mesenteric adipose tissue, and in capillaries of the heart and skeletal muscle [26]. A Mendelian randomization study examining the missense variants in SLC5A1, which is associated with a decrease in SGLT1 function, has shown decreased incidence of type 2 diabetes, obesity, heart failure, and death. Visceral obesity is a risk factor for MI and stroke, and it may cause an increase in inflammatory cytokines, leptin, endothelial dysfunction, and thrombosis [27]. SGLT1 levels are increased in patients with type 2 diabetes [28]. Selective SGLT1 inhibition in the early intestine results in increased glucose delivery to the distal intestine and colon [29–32], where it reduces colonic pH and is metabolized by the gut microbiome, resulting in an increase in short chain fatty acids (SCFA) [33]. A reduction in intestinal glucose absorption and its increased delivery to the distal intestines as a result of SGLT1 inhibition is also linked to a sustained increase in GLP-1 [31]. An increase in native GLP-1 can suppress thrombus growth at both venous and arterial shear rates [19] as well as increase atherosclerotic plaque stability [20]. In view of the reduction in incidence of MI and stroke in SCORED and SOLOIST [5, 6]—greater than that seen with the SGLT2is [3] and many GLP-1 RAs [4, 34]—it is likely that mechanisms other than reduction in blood pressure, visceral obesity, myocardial oxygen demand, and increase in GLP-1 explain this reduction. Other aspects of SGLT1 inhibition may also play an important role.

The development of MI and stroke could be affected by alterations in the intestinal microbiome as a result of SGLT1 inhibition and an increase in delivery of glucose to the distal intestines. Alterations in the gut microbiome associated with obesity and type 2 diabetes trigger inflammation, intestinal permeability, and insulin sensitivity [35]. Aging can cause a decrease in SCFAs in the intestinal microbiome, which is linked to an increase in inflammatory cytokines and weakening of immune defenses [36]. An increase in bacterial lipopolysaccharides (LPS) is associated with an increase in coagulation. LPS binds to toll-like receptors to activate endothelial cells and platelets, leading to activation of the coagulation cascade [37]. The microbiome also produces trimethylamine-N-oxide (TMAO), which causes an increase in platelet activation, thrombosis, and cardiovascular risk [38]. TMAO levels are increased at admission in patients with ischemic stroke and then decrease after 48 h [39]. An increase in TMAO levels is also associated with an increase in 5-year all-cause mortality in patients with stable coronary artery disease [40].

Alterations in the intestinal microbiome as a result of SGLT1 inhibition are of potential importance and deserve further exploration. However, the expression of SGLT1 in the brain and heart [26] is likely connected to the effect that SGLT1 inhibition with sotagliflozin has on stroke and MI.

Cerebral ischemia increases the permeability of the blood–brain barrier (BBB), which increases cerebral edema [41]. SGLT1 expression is increased in cultured endothelial cells from small vessels in the bovine brain under hypoxic conditions [42]. Administration of intracerebral ventricular phlorizin [43, 44] as well as intracerebral ventricular administration of antisense SGLT1mRNA [45] reduced infarct size and cognitive deficits after medial cerebral artery occlusion (MCAO).

Cardiac overexpression of SGLT1 increases myocyte size, collagen 1 gene expression, and interstitial fibrosis in mouse hearts subjected to ischemia, independent of glucose [46]. SGLT1 knockdown demonstrably protected the heart from ischemic-reperfusion injury in mice [47]. Importantly, pretreatment of mice with the selective SGLT1 inhibitor KGA-2727 protected against cardiac remodeling and heart failure in mice after left anterior descending coronary artery occlusion [46]. Phlorizin, a non-selective SGLT inhibitor shown to also block SGLT1, increases infarct size in mice [48]. However, phlorizin’s effect on ischemic-reperfusion injury has been suggested to be due to its effects on glucose transporters in contrast to its effect on SGLT1 [47].

The undetermined mechanisms linking SGLT1 inhibition to MI and stroke necessitate further exploration. Considering the effect of SGLT1 inhibition on the intestinal microbiome as well as the direct effect of inhibition of SGLT1 expression in the heart and brain, there are several ways that SGLT1 inhibition could favorably alter the risk of thrombosis (Fig. 1).

Fig. 1.

Fig. 1

Open in a new tab

Effects of SGLT1/2 inhibition and GLP-1 receptor agonism on the incidence of myocardial infarction and stroke in patients with type 2 diabetes mellitus. BBB, blood brain barrier; Hct, hematocrit; MI, myocardial infarction; ROS, reactive oxygen species

The adverse effects of adding SGLT1 to SGLT2 inhibition with sotagliflozin resemble those of the SGLT2is alone. All these drugs increase the risk of mycotic genital infections, have an increased but rare incidence of diabetic ketoacidosis, and are associated with a transient hemodynamically mediated decrease but long-term benefit in eGFR [3, 5]. As expected from the expression of SGLT1 in the small intestine, sotagliflozin is also associated with a 2.5–2.8% increase in diarrhea as well as a significant increase in volume depletion (1.3%) and hypotension [5, 6].

Larger and longer studies are required to confirm the effectiveness of combined SGLT1/SGLT2 inhibition in reducing MI and stroke in patients with type 2 diabetes and elucidate the mechanisms associated with this finding. Thus far, the results from SCORED and SOLOIST suggest that an increase in SGLT1 inhibition when added to SGLT2 inhibition may contribute to the reduction in MI and stroke in patients with type 2 diabetes [5, 6]. This benefit is beyond what SGLT2is alone can accomplish and at least similar to GLP-1 RAs but with the added benefit of a reduction in hospitalizations and urgent visits for HF. However, the role of SGLT1/2 inhibition with sotagliflozin as an addition to GLP-1 RA in patients with and without type 2 diabetes at increased risk for stroke and MI remains to be studied. Regardless, finding that a relative increase in SGLT1/SGLT2 inhibition reduces the risk of MI and stroke as well as hospitalizations and urgent visits for heart failure provides an opportunity to further improve quality of life for patients and reduce the healthcare burden associated with type 2 diabetes [49].

Data Availability Statement

No new data were generated or analyzed in support of this review.

Code Availability

Not applicable.

Declarations

Conflict of Interest

Dr. Pitt served as co-chair of SOLOIST, was on the executive committee of SCORED, and received consulting fees from Sanofi/Lexicon. In addition, Dr. Pitt discloses the following relationships—consulting fees: Bayer, Astra Zeneca, Boehringer Ingelheim/Lilly, Merck, and Phasebio. Consulting fees + stock options: SCPharmaceuticals, SQinnovations, G3pharmaceuticals, Relypsa/Vifor, Cereno scientific, KBP Pharmaceuticals, Sarfez, Tricida, Proton Intel, and Brainstorm Medical. He is chairman of the steering committee of the NHLBI TRANSFORM trial and co-chair of the NHLBI–Swedish Heart Foundation SPIRRIT trial. He holds US Patent 9931412 on site specific delivery of eplerenone to the myocardium and pending US Patent 63/045,784 on histone-acetylation-modulating agents for the treatment and protection of organ damage.

Dr. Steg discloses the following relationships: research grant from Amarin, Bayer, Sanofi, and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Bristol-Myers-Squibb, Idorsia, Myokardia, Novartis, Novo-Nordisk, PhaseBio, Pfizer, Regeneron, Sanofi, Servier.

Dr. Leiter was a member of the Executive Committee of SOLOIST and SCORED and received research funding from, provided CME on behalf of, and/or acted as an adviser to AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Lexicon, Merck, Novo Nordisk, Sanofi, and Servier.

Dr. Bhatt served as the chair of SOLOIST and SCORED, with research funding from Sanofi and then Lexicon paid to Brigham and Women’s Hospital. Dr. Bhatt discloses the following relationships—advisory board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; chair: inaugural chair, American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Novartis, Population Health Research Institute; honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); site co-investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte; Trustee: American College of Cardiology; unfunded research: FlowCo, Merck, Takeda.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

12/24/2021

A Correction to this paper has been published: 10.1007/s10557-021-07308-6

References

  • 1.Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2020;76:1117–1145. doi: 10.1016/j.jacc.2020.05.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Eur Heart J. 2020;41(2):255–323. doi: 10.1093/eurheartj/ehz486. [DOI] [PubMed] [Google Scholar]
  • 3.McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–158. doi: 10.1001/jamacardio.2020.4511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Marsico F, Paolillo S, Gargiulo P, et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41(35):3346–3358. doi: 10.1093/eurheartj/ehaa082. [DOI] [PubMed] [Google Scholar]
  • 5.Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39. [DOI] [PubMed]
  • 6.Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28. [DOI] [PubMed]
  • 7.Pitt B, Bhatt DL. Can SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes mellitus? Circulation. 2021;144:4–6. doi: 10.1161/CIRCULATIONAHA.121.054442. [DOI] [PubMed] [Google Scholar]
  • 8.Gilbert RE, Connelly KA. Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovasc Diabetol. 2019;18:6–9. doi: 10.1186/s12933-019-0812-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ali A, Bain S, Hicks D, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10(5):1595–1622. doi: 10.1007/s13300-019-0657-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.The blood pressure lowering treatment trialists’ collaboration Lancet. 2021;397(10285):1625–1636. doi: 10.1016/S0140-6736(21)00590-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sano M, Goto S. Possible mechanisms of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–1987. doi: 10.1161/CIRCULATIONAHA.118.038881. [DOI] [PubMed] [Google Scholar]
  • 12.Yang R, Wang A, Ma L, et al. Hematocrit and the incidence of stroke: a prospective, population-based cohort study. Ther Clin Risk Manag. 2018;14:2081–2088. doi: 10.2147/TCRM.S174961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized, placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X. [DOI] [PubMed] [Google Scholar]
  • 14.Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141. [DOI] [PubMed] [Google Scholar]
  • 15.Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med. 2019;381:841–851. doi: 10.1056/NEJMoa1901118. [DOI] [PubMed] [Google Scholar]
  • 16.Trevisan M, Fu EL, Szummer K, et al. Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Heart J. 2021;7(2):104–111. doi: 10.1093/ehjcvp/pvaa004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation. 2021;143:770–779. doi: 10.1161/CIRCULATIONAHA.120.047965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sayour AA, Celeng C, Oláh A, Ruppert M, Merkely B, Radovits T. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis. Diabetologia. 2021;64(4):737–748. doi: 10.1007/s00125-020-05359-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sternkopf M, Nagy M, Baaten CCFMJ, et al. Native intact glucagon-like peptide is a natural suppressor of thrombus growth under physiologic flow conditions. Arterioscler Thromb Vasc Biol. 2020; e65-e77. 10.1161/ATVBAHA.119.313645. [DOI] [PubMed]
  • 20.Burgmaier M, Liberman A, Möllmann J, Kahles F, Reith S, Lebherz C, Marx N, Lehrke M. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9–37) and GLP-1(28–37) stabilize atherosclerotic lesions in apoe-/-mice. Atherosclerosis. 2013;231(2):427–435. doi: 10.1016/j.atherosclerosis.2013.08.033. [DOI] [PubMed] [Google Scholar]
  • 21.Avogaro A, Bonora E, Consoli A, Del Prato S, Genovese S, Giorgino F. Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diab Vasc Dis Res. 2019;16(5):399–414. doi: 10.1177/1479164119845612. [DOI] [PubMed] [Google Scholar]
  • 22.Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016;118(11):1808–1829. doi: 10.1161/CIRCRESAHA.116.306923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Tun NN, Arunagirinathan G, Munshi SK, Pappachan JM. Diabetes mellitus and stroke: a clinical update. World J Diabetes. 2017;8(6):235–248. doi: 10.4239/wjd.v8.i6.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cui J, Liu Y, Li F, Xu F, Liu Y. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Front Cardiovas Med. 2021;8:644189. doi: 10.3389/fcvm.2021.644189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kelly DM, Rothwell PM. Does chronic kidney disease predict stroke risk independent of blood pressure?: a systematic review and meta-regression. Stroke. 2019;50(11):3085–3092. doi: 10.1161/STROKEAHA.119.025442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111–118. doi: 10.1093/cvr/cvp190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Seidelmann SB, Feofanova E, Yu B, et al. Genetic variations in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol. 2018;72(15):1763–1773. doi: 10.1016/j.jacc.2018.07.061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dyer J, Wood IS, Palejwala A, Ellis A, Shirazi-Beechey SP. Expression of monosaccharaide transporters in intestine of diabetic humans. J Physiol Gastrointest Liver Physiol. 2002;282(2):G241–248. doi: 10.1152/ajpgi.00310.2001. [DOI] [PubMed] [Google Scholar]
  • 29.Goodwin NC, Ding ZM, Harrison BA, et al. Discovery of LX2761, a sodium-dependent glucose co-transporter 1 (SGLT1) inhibitor restricted to the intestinal lumen, for the treatment of diabetes. J Med Chem. 2017;60(2):710–721. doi: 10.1021/acs.jmedchem.6b01541. [DOI] [PubMed] [Google Scholar]
  • 30.Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol. 2015;308(11):G946–954. doi: 10.1152/ajpgi.00286.2014. [DOI] [PubMed] [Google Scholar]
  • 31.Oguma T, Nakayama K, Kuriyama C, et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther. 2015;354(3):279–289. doi: 10.1124/jpet.115.225508. [DOI] [PubMed] [Google Scholar]
  • 32.Gorboulev V, Schürmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretion secretion. Diabetes. 2012;61(1):187–196. doi: 10.2337/db11-1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rieg JAD, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition. Diabetes Obes Metab. 2019;21(suppl 2):43–52. doi: 10.1111/dom.13630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3. [DOI] [PubMed] [Google Scholar]
  • 35.Aw W, Fukuda S. Understanding the role of the gut ecosystem in diabetes mellitus. J Diabetes Investig. 2018;9(1):5–12. doi: 10.1111/jdi.12673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Nagpal R, Mainali R, Ahmadi S, et al. Gut microbiome and aging: physiological and mechanistic insights. Nutr Healthy Aging. 2018;4(4):267–285. doi: 10.3233/NHA-170030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hasan RA, Koh AY, Zia A. The gut microbiome and thromboembolism. Thromb Res. 2020;189:77–87. doi: 10.1016/j.thromres.2020.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–124. doi: 10.1016/j.cell.2016.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Schneider C, Okun JG, Schwarz KV, et al. Trimethylamine-N-oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days. Eur J Neurol. 2020;27(8):1596–1603. doi: 10.1111/ene.14253. [DOI] [PubMed] [Google Scholar]
  • 40.Senthong V, Wang Z, Li XS, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc. 2016;5(6):e002816. doi: 10.1161/JAHA.115.002816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Koepsell H. Glucose transporters in brain in health and disease. Pflugers Arch. 2020;472:1299–1343. doi: 10.1007/s00424-020-02441-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Vemula S, Roder KE, Yang T, Bhat J, Thekkumkara TJ, Abbruscato TJ. A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther. 2009;328(2):487–495. doi: 10.1124/jpet.108.146589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Yamazaki Y, Harada S, Tokuyama S. Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter. Brain Res. 2012;1489:113–120. doi: 10.1016/j.brainres.2012.10.020. [DOI] [PubMed] [Google Scholar]
  • 44.Yamazaki Y, Ogihara S, Harada S, Tokuyama S. Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia. Neuroscience. 2015;310:674–685. doi: 10.1016/j.neuroscience.2015.10.005. [DOI] [PubMed] [Google Scholar]
  • 45.Yamazaki Y, Harada S, Wada T, Yoshida S, Tokuyama S. Sodium transport through the cerebral sodium-glucose transporter exacerbates neuron damage during cerebral ischaemia. J Pharm Pharmacol. 2016;68(7):922–931. doi: 10.1111/jphp.12571. [DOI] [PubMed] [Google Scholar]
  • 46.Sawa Y, Saito M, Ishida N, et al. Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice. J Pharmacol Sci. 2020;142(1):16–25. doi: 10.1016/j.jphs.2019.11.001. [DOI] [PubMed] [Google Scholar]
  • 47.Li Z, Agrawal V, Ramratnam V, et al. Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia/reperfusion injury. Cardiovasc Res. 2019;115(11):1646–1658. doi: 10.1093/cvr/cvz037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kashiwagi Y, Nagoshi T, Yoshino T, et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS ONE. 2015;10(6):e0130605. doi: 10.1371/journal.pone.0130605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Szarek M, Bhatt DL, Steg PG, et al. Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial. Ann Intern Med. 2021 Jun 22. [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No new data were generated or analyzed in support of this review.

Not applicable.

Articles from Cardiovascular Drugs and Therapy are provided here courtesy of Springer

RESOURCES